第16周血清度普利尤单抗水平与特应性皮炎患者治疗反应及不良反应的关联:来自BioDay登记的前瞻性临床队列研究
该前瞻性观察性队列研究纳入295例使用度普利尤单抗治疗的特应性皮炎成人患者,检测第16周血清药物水平并分析其与第52周治疗反应及第一年不良反应的关联。结果显示第16周血清度普利尤单抗水平中位数为86.6 μg/mL,与EASI 90、EASI≤7及不良反应均无显著关联。
要点
- 第16周血清度普利尤单抗水平中位数为86.6 μg/mL(IQR 64.6-110.0 μg/mL)。
- 不同EASI反应状态(<50、50、75、90)间血清度普利尤单抗水平无显著差异。
- 第16周血清水平预测第52周EASI≥90、EASI≤7及不良反应的OR均不显著。
核心结论
- 本前瞻性临床队列研究发现第16周血清度普利尤单抗水平范围较广,且与治疗第一年的治疗反应和不良反应均无关联。
- 作者认为治疗反应可能取决于白细胞介素-4受体α亚基的靶点可及性,患者间差异导致反应异质性。
研究设计与样本
- 本研究为前瞻性观察性临床队列研究,使用BioDay登记数据,纳入开始度普利尤单抗治疗且第16周有血清样本的成人特应性皮炎患者。
- 所有患者均按荷兰乌得勒支大学医学中心BioDay方案治疗:度普利尤单抗600 mg皮下负荷剂量,随后每2周300 mg。
- 第16周前调整剂量或停止治疗的患者被排除;数据分析于2022年1月至6月进行。
- 共纳入295例患者,平均(SD)年龄41.5(15.9)岁,170例(57.6%)为男性。
主要发现
- 第16周血清度普利尤单抗水平中位数(IQR[范围])为86.6 μg/mL(64.6-110.0 μg/mL[10.1-382.0 μg/mL])。
- 第16周不同应答状态(EASI<50、50、75、90)间血清度普利尤单抗水平无显著差异。
- 多因素logistic回归显示第16周血清度普利尤单抗水平预测长期EASI≥90的OR为0.96(95%CI 0.90-1.04;P=0.34),无统计学显著性。
- 预测长期EASI≤7的OR为1.03(95%CI 0.93-1.14;P=0.55),无统计学显著性。
- 预测不良反应的OR为1.01(95%CI 0.95-1.07;P=0.83),无统计学显著性。
关键数值与推荐
- 治疗反应定义为EASI评分较基线下降百分比(如EASI 90表示下降90%)以及绝对EASI≤7(控制性AD)。
- 多因素logistic回归模型纳入年龄和性别作为协变量,评估第16周血清度普利尤单抗水平对第52周反应(EASI 90;EASI≤7)和不良反应的预测。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The registered dose of dupilumab for adult patients with atopic dermatitis (AD) is 300 mg every other week. At present, it is unknown whether serum dupilumab levels are associated with treatment response or adverse effects. OBJECTIVES: To evaluate serum dupilumab levels at 16 weeks of treatment and to explore the association of serum dupilumab levels with treatment response and adverse effects in patients with AD. DESIGN, SETTING, AND PARTICIPANTS: This clinical, prospective, observational cohort study used data from the prospective BioDay Registry including adult patients with AD who started dupilumab treatment and for whom a serum sample was available at 16 weeks of treatment. All patients were treated according to the BioDay protocol in the University Medical Center Utrecht in the Netherlands. Patients received a loading dose of dupilumab 600 mg subcutaneously, followed by 300 mg every other week. Patients who had a dose adjustment or discontinued treatment before 16 weeks of treatment were excluded. Data analyses were performed from January to June 2022. MAIN OUTCOMES AND MEASURES: Disease severity of AD was assessed at baseline and at weeks 16 and 52 using the Eczema Area and Severity Index (EASI). Treatment response was defined as the percent reduction in EASI score vs the baseline score (eg, EASI 90 indicated a 90% reduction) and as an absolute EASI cutoff score of 7 or lower (controlled AD). Adverse effects were recorded during the first year. At 16 weeks, dupilumab serum levels and treatment responses were measured and analyzed. Multivariate logistic regression modeling was used to determine the prediction of response (EASI 90; EASI ≤7) and adverse effects at 52 weeks, with serum dupilumab levels at 16 weeks in the presence of the covariates age and sex. RESULTS: Among the total of 295 patients with AD (mean [SD] age, 41.5 [15.9] years; 170 [57.6%] men), the median (IQR [range]) drug level was 86.6 μg/mL (64.6-110.0 μg/mL [10.1-382.0 μg/mL]) at 16 weeks of treatment. No significant differences were found in serum dupilumab levels between responder statuses (EASI, <50, 50, 75, or 90) at week 16. Multivariate logistic regression analysis showed nonsignificant odds ratios (ORs) for serum dupilumab levels at 16 weeks regarding prediction of long-term response (EASI ≥90: OR, 0.96 [95% CI, 0.90-1.04; P = .34] and EASI ≤7: OR, 1.03 [95% CI, 0.93-1.14; P = .55]) and adverse effects (OR, 1.01 [95% CI, 0.95-1.07; P = .83]). CONCLUSION AND RELEVANCE: This prospective clinical cohort study found a broad range of serum dupilumab levels at 16 weeks of treatment and no association with treatment response and adverse effects during first year of treatment. Response may be dependent on target availability of the interleukin-4 receptor subunit α, with an interpatient variability producing heterogeneity in response.
引用
- Spekhorst LS, de Graaf M, Loeff F, et al. Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis: A Prospective Clinical Cohort Study From the BioDay Registry. JAMA Dermatol. 2022. PMID: 36322072. doi:10.1001/jamadermatol.2022.4639
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。